Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis

Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Rainer Porschen(Klinikum Bremen-Mitte), Axel Grothey(Campbell Clinic), Werner Freier(Mayo Clinic in Florida), Thomas Seufferlein(Universität Ulm), Ullrich Graeven(Kliniken Maria Hilf), Axel Hinke, Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Albrecht Kretzschmar(Roche (Switzerland)), Stefan Kubicka(Medizinische Hochschule Hannover)
Journal of Clinical Oncology
June 1, 2005
10.1200/jco.2005.23.16_suppl.3507
Cited by 42

Related Papers

Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k